Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 8/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403602 | 1.00 | CALML3 (0.54) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL6397416 | 0.89 | MAOA (0.56) | CALML3MAOAMAOB | |
| SCHEMBL6397412 | 0.89 | MAOA (0.56) | CALML3MAOAMAOB | |
| SCHEMBL6399077 | 0.89 | CALML3 (0.41) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL6399072 | 0.89 | CALML3 (0.41) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL6397079 | 0.79 | CALML3 (0.55) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL27371358 | 0.79 | CALML3 (0.55) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL8551980 | 0.78 | CALML3 (0.53) | CALML3CYP2C19CYP2C9MAOAMAOB | |
| SCHEMBL5327254 | 0.78 | MAOB (0.53) | CALML3MAOAMAOB | |
| SCHEMBL1498683 | 0.78 | MAOB (0.53) | CALML3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | HUTCHINSON DOUGLAS K (US) | 2005-03-10 | — | — | US | disclosed |
| US-6358942-B1 | MICROBIOCIDES AND BACTERICIDES FOR TREATING GRAMPOSITIVE, BACTEROIDES, CLOSTRIDIUM, MYCOBACTERIUM, STAPHYLOCOCCUS AND STREPTOCOCCUS INFECTIONS | PHARMACIA & UPJOHN COMPANY | 2002-03-19 | — | — | US | disclosed |
| US-6313307-B1 | DEBLOCKING, DEPROTECTING; CATALYTIC HYDROGENATION, ALKYLATION; PREPARING MICROBIOCIDES AGAINST STAPHYLOCOCCUS, STREPTOCOCCUS, MYCOBACTERIUM, AND CLOSTRIDIUM | PHARMACIA & UPJOHN COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-0856002-B1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | UPJOHN CO (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6166056-A | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | PHARMACIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-6051716-A | ANTIMICROBIAL AGENTS | PHARMACIA & UPJOHN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6043266-A | MICROBIOCIDES TREATING GRAM-POSITIVE BACTERIA INFECTIONS AND PERSONS WITH AIDS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| US-5968962-A | ANTIMICROBIAL AGENTS; EFFECTIVE AGAINST GRAMPOSITIVE BACTERIA | PHARMACIA & UPJOHN COMPANY (US) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054683-A1 | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings | CBR1, NCOR1, RCOR1 | CALML3 3240/4885CYP2C19 136/4885CYP2C9 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.